Tenax Therapeutics (TENX) EBIT (2010 - 2026)
Tenax Therapeutics recorded quarterly EBIT of -$16.6 million in Q1 2026, down 0.75% quarter-over-quarter from -$16.4 million in Q4 2025, and down 46.17% year-over-year from -$30.8 million in Q1 2025.
Tenax Therapeutics' EBIT history runs 16 years deep, the most recent figure standing at -$16.6 million for Q1 2026.
- In Q1 2026, EBIT fell 46.17% year-over-year to -$16.6 million; the TTM figure through Mar 2026 stood at -$61.6 million (down 128.87% YoY), while the FY2025 annual figure was -$56.4 million, down 189.24% from the prior year.
- EBIT came in at -$16.6 million for Q1 2026 at Tenax Therapeutics, down from -$16.4 million in the prior quarter.
- In the past five years, EBIT ranged from a high of $2.9 million in Q3 2022 to a low of -$16.8 million in Q3 2025.
- A 5-year average of -$5.5 million and a median of -$3.9 million in 2024 frame the typical range for EBIT.
- Across the five-year window, EBIT surged 104.1% in 2022 and plunged 613.85% in 2023, its largest moves.
- Tenax Therapeutics' EBIT stood at $2.6 million in 2022, then slumped by 613.85% to -$13.1 million in 2023, then soared by 44.43% to -$7.3 million in 2024, then plunged by 125.48% to -$16.4 million in 2025, then decreased by 0.75% to -$16.6 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$16.6 million, -$16.4 million, and -$16.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - | -16.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.57 Mn |
| Dec 31, 2025 | -16.45 Mn |
| Sep 30, 2025 | -16.81 Mn |
| Jun 30, 2025 | -11.79 Mn |
| Mar 31, 2025 | -11.34 Mn |
| Dec 31, 2024 | -7.30 Mn |
| Sep 30, 2024 | -4.62 Mn |
| Jun 30, 2024 | -3.67 Mn |
| Mar 31, 2024 | -3.91 Mn |
| Dec 31, 2023 | -13.13 Mn |
| Sep 30, 2023 | 2.12 Mn |
| Jun 30, 2023 | 1.24 Mn |
| Mar 31, 2023 | -1.54 Mn |
| Dec 31, 2022 | 2.55 Mn |
| Sep 30, 2022 | 2.92 Mn |
| Jun 30, 2022 | 2.86 Mn |
| Mar 31, 2022 | 2.72 Mn |
| Dec 31, 2021 | -62.24 Mn |
| Sep 30, 2021 | 3.80 Mn |
| Jun 30, 2021 | 1.96 Mn |
| Mar 31, 2021 | 23.75 Mn |
| Dec 31, 2020 | 2.83 Mn |
| Sep 30, 2020 | 2.23 Mn |
| Jun 30, 2020 | 2.14 Mn |
| Mar 31, 2020 | 2.67 Mn |
| Dec 31, 2019 | -14.30 Mn |
| Sep 30, 2019 | 2.26 Mn |
| Jun 30, 2019 | 1.82 Mn |
| Mar 31, 2019 | 1.66 Mn |
| Dec 31, 2018 | -11.56 Mn |
| Sep 30, 2018 | 1.55 Mn |
| Jun 30, 2018 | 1.89 Mn |
| Mar 31, 2018 | 1.22 Mn |
| Dec 31, 2017 | -17.03 Mn |
| Sep 30, 2017 | 1.31 Mn |
| Jun 30, 2017 | 3.01 Mn |
| Mar 31, 2017 | 3.50 Mn |
| Dec 31, 2016 | -67.53 Mn |
| Sep 30, 2016 | 4.50 Mn |
| Jun 30, 2016 | 4.67 Mn |
| Mar 31, 2016 | -5.71 Mn |
| Dec 31, 2015 | -10.43 Mn |
| Sep 30, 2015 | -3.10 Mn |
| Jun 30, 2015 | -4.87 Mn |
| Apr 30, 2013 | -1.24 Mn |
| Jan 31, 2013 | -1.59 Mn |
| Oct 31, 2012 | -682,843.00 |
| Jul 31, 2012 | -1.68 Mn |
| Apr 30, 2012 | -1.86 Mn |
| Jan 31, 2012 | -1.87 Mn |
| Oct 31, 2011 | -2.05 Mn |
| Jul 31, 2011 | -2.43 Mn |
| Apr 30, 2011 | 2.73 Mn |
| Jan 31, 2011 | 2.75 Mn |
| Oct 31, 2010 | 2.06 Mn |
| Jul 31, 2010 | 3.02 Mn |